CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients-Reference-Cited by-同舟云学术

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients

Published:2015-12-30 Issue:4 Volume:86 Page:375-381
ISSN:0028-3878
Container-title:Neurology
language:en
Short-container-title:Neurology

Author:

Lieberman Linda A.,Zeng Wanyong,Singh Carol,Wang Wenting,Otipoby Kevin L.,Loh Christine,Plavina Tatiana,Gorelik Leonid,Ransohoff Richard M.,Cahir-McFarland Ellen

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Neurology (clinical)

Reference9 articles.

1. Review: Natalizumab in the treatment of multiple sclerosis

2. Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

3. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients

4. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study

5. Optimization and Limitations of Use of Cryopreserved Peripheral Blood Mononuclear Cells for Functional and Phenotypic T-Cell Characterization

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience;Journal of Central Nervous System Disease;2022-01

2. Immunoprofiling of early, untreated rheumatoid arthritis using mass cytometry reveals an activated basophil subset inversely linked to ACPA status;Arthritis Research & Therapy;2021-10-29

3. Progressive multifocal leukoencephalopathy in an elderly immunocompetent-appearing patient: Relevance with L-selectin (CD62L) expression and immunosenescence;Clinical Neurology and Neurosurgery;2021-06

4. New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab;Frontiers in Neurology;2020-12-17

5. High effector-memory CD8+ T-cell levels correlate with high PML risk in natalizumab-treated patients;Multiple Sclerosis and Related Disorders;2020-11